Christopher Hite, Evp & Chairman, Partnering at Royalty Pharma plc (RPRX), reported a sale of 100,000 shares on August 18, 2026. The transaction, valued at approximately $6.00 million, was executed at an average price of $59.97 per share.
This sale adds to recent insider selling activity at Royalty Pharma. Earlier in the year, Marshall Urist also reported a sale of 9,099 shares, and Mr. Hite himself had multiple transactions in June.
Insider sales can be driven by various factors including portfolio diversification, tax obligations, or pre-arranged trading plans and do not necessarily reflect a negative outlook on the company's performance.